This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer|Female Breast Cancer
Interventions: DRUG: FCN-437c, Letrozole or anastrozole, Goserelin acetate|DRUG: Placebo, Letrozole or anastrozole, Goserelin acetate
Sponsor: Ahon Pharmaceutical Co., Ltd.